This is a Phase 1 clinical trial that aims to evaluate the safety, tolerability, and efficacy of a drug called axitinib in the OTX-TKI implant in participants with wet AMD.
Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years of age. In the wet form of AMD, abnormal blood vessels grow in the back of the eye leaking blood or fluid that causes blurred or distorted vision.
The Queensland Eye Institute is currently involved in a phase 1 clinical trial that aims to evaluate the safety, tolerability, and efficacy of a drug called axitinib in the OTX-TKI implant in participants with wet AMD. The principal investigator involved in this study is A/Prof Anthony Kwan and the associate investigator involved is Dr Abhishek Sharma.
50 years
Both
Lorem ipsum set emit dolor
Your support will help us recruit the best researchers to develop better treatments, purchase the latest equipment, advance clinical trials of new treatments, improve eye health education, and support talented students to become tomorrow’s leaders in eye research.